Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation.

A prospective evaluation of neoadjuvant hormonal downsizing in patients with localized carcinoma of the prostate was undertaken to assess its effect on normal tissue irradiation. Twenty patients with stage T1 or T2 (A, B) carcinoma of the prostate received 3 months of Lupron prior to definitive radiotherapy. The volumes of the prostate, seminal vesicles, bladder, and rectum from both the pre- and posthormone treatment planning CT were entered onto a 3-D treatment-planning system. The treatment planning parameters were standardized to facilitate comparison of the pre- and posthormonal volumes. Following the three monthly injections of Lupron, the average volume of the prostate was reduced by 37%. As a consequence, the volume of the bladder receiving at least 40, 52, and 64 Gy was reduced by an average of 15, 18, and 20%, respectively. In addition, the volume of the rectum receiving at least 40, 52, and 64 Gy was reduced by an average of 13, 20, and 34%, respectively. In conclusion, in patients with localized prostate cancer, downsizing of the prostate resulted in a reduction in the volume of bladder and rectum receiving high radiation doses. This approach may result in an improvement in the therapeutic ratio by reducing the morbidity of treatment.

[1]  J. Montie,et al.  Frequency of residual neoplasm in the prostate following three‐dimensional conformal radiotherapy , 1993, The Prostate.

[2]  J. Forman,et al.  Improving the therapeutic ratio of external beam irradiation for carcinoma of the prostate. , 1985, International journal of radiation oncology, biology, physics.

[3]  G. Edmundson,et al.  Pelvic lymphadenectomy and transperineal interstitial implantation of IR 192 combined with external beam radiotherapy for bulky stage C prostatic carcinoma. , 1989, International journal of radiation oncology, biology, physics.

[4]  T. Griffin.  Fast neutron radiation therapy. , 1992, Critical reviews in oncology/hematology.

[5]  Mageras,et al.  Three-Dimensional Conformal Radiation Therapy at the Memorial Sloan-Kettering Cancer Center. , 1992, Seminars in radiation oncology.

[6]  H. Sandler,et al.  Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Forman,et al.  Advantages of CT and beam's eye view display to confirm the accuracy of pelvic lymph node irradiation in carcinoma of the prostate. , 1993, Radiology.

[8]  H. Sandler,et al.  3D conformal radiotherapy for the treatment of prostate cancer: Low risk of chronic rectal morbidity observed in a large series of patients , 1993 .

[9]  G. Ezzell,et al.  Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.